D
Foghorn Therapeutics Inc.
FHTX
$4.45
-$0.13-2.84%
D
Sell
5/15/2023Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D- from E+ on 5/15/2023 due to a noticeable increase in the valuation index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D- from E+ on 5/15/2023 due to a noticeable increase in the valuation index.
E
Sell
3/14/2023Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.27 to 53.3, operating cash flow declined 44.72% from -$19.99M to -$28.92M, and total revenue declined 36.93% from $6.63M to $4.18M.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.27 to 53.3, operating cash flow declined 44.72% from -$19.99M to -$28.92M, and total revenue declined 36.93% from $6.63M to $4.18M.
D
Sell
2/9/2023Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.12 to 0.27, and the quick ratio declined from 8.23 to 6.77.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.12 to 0.27, and the quick ratio declined from 8.23 to 6.77.
D
Sell
5/16/2022Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and valuation index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.07 to 0.08, and the quick ratio declined from 9.33 to 8.8.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.07 to 0.08, and the quick ratio declined from 9.33 to 8.8.
D
Sell
5/4/2022Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 05/04/2022.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.7054 to -$0.766, and EBIT declined 6.93% from -$26.26M to -$28.08M.
Foghorn Therapeutics Inc. (FHTX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.7054 to -$0.766, and EBIT declined 6.93% from -$26.26M to -$28.08M.
D
Sell
11/9/2021Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/3/2021Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index.
D
Sell
7/1/2021Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to D- from E on 7/1/2021 due to an increase in the valuation index.
Foghorn Therapeutics Inc. (FHTX) was upgraded to D- from E on 7/1/2021 due to an increase in the valuation index.
E
Sell
3/19/2021Upgraded
Foghorn Therapeutics Inc. (FHTX) was upgraded to E from E- on 3/19/2021 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 3.5 to 9.86, earnings per share increased from -$3.1215 to -$0.7487, and total revenue increased 40.22% from $179 to $251.
Foghorn Therapeutics Inc. (FHTX) was upgraded to E from E- on 3/19/2021 due to a significant increase in the solvency index, growth index and volatility index. The quick ratio increased from 3.5 to 9.86, earnings per share increased from -$3.1215 to -$0.7487, and total revenue increased 40.22% from $179 to $251.
E
Sell
3/10/2021Downgrade
Foghorn Therapeutics Inc. (FHTX) was downgraded to E- from E on 3/10/2021 due to a large decline in the volatility index.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E- from E on 3/10/2021 due to a large decline in the volatility index.
E
Sell
1/20/2021None
Foghorn Therapeutics Inc. (FHTX) was downgraded to E from U on 01/20/2021.
Foghorn Therapeutics Inc. (FHTX) was downgraded to E from U on 01/20/2021.
NASDAQ
03/13/2025 12:29PM Eastern
Quotes delayed
